Diabetic Kidney Disease– A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)

The incidence and prevalence of diabetes mellitus (DM) continue to grow dramatically throughout the world, due primarily to the increase in type 2 DM (T2DM). Although improvements in DM and hypertension management have reduced the proportion of diabetic individuals who develop chronic kidney disease (CKD) and progress to end-stage renal disease (ESRD), the sheer increase in people developing DM will have a major impact on dialysis and transplant needs. This KDIGO conference addressed a number of controversial areas in the management of DM patients with CKD, including aspects of screening for CKD with measurements of albuminuria and estimated glomerular filtration rate (eGFR); defining treatment outcomes; glycemic management in both those developing CKD and those with ESRD; hypertension goals and management, including blockers of the renin-angiotensin-aldosterone system; and lipid management. Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms Correspondence: Mark E. Molitch, MD, Division of Endocrinology, Metabolism & Molecular Medicine, Northwestern University Feinberg School of Medicine, 645 N. Michigan Avenue, Suite 530 Chicago, IL 60611, USA, [email protected]. DISCLOSURES Dr. de Zeeuw declared having served as a consultant for and received honoraria (to employer) from AbbVie, Astellas, AstraZeneca, ChemoCentryx, HemoCue, Johnson & Johnson, Novartis, Reata, and Takeda. Dr. Kasiske declared having received consultancy fees from Litholink/Labcorp, Medscape (supported by Astellas), and Rockpointe (supported by Astellas and Novartis). Dr. Molitch declared having received consultancy fees from Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Novartis and Novo Nordisk and research funding from Bayer, Novartis, Novo Nordisk, and Reata. Dr. Wanner declared having received speaker honoraria from Astellas-Pfizer (Japan), Merck, and Merck Sharpe & Dohme. Dr. Wheeler declared having received consultancy fees from Amgen, Astellas, Baxter, Merck Sharp and Dohme, Otsuka, and Vifor; research funding from Abbott, AstraZeneca, Genzyme (monies all paid to institution); honoraria from Abbott, Amgen, Astellas, Fresenius Medical Care, Genzyme, Otsuka and Shire. Drs. Adler, Flyvbjerg, Mogensen, Nelson and So reported no relevant disclosures. HHS Public Access Author manuscript Kidney Int. Author manuscript; available in PMC 2015 July 01. Published in final edited form as: Kidney Int. 2015 January ; 87(1): 20–30. doi:10.1038/ki.2014.128. A uhor M anscript